meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
2
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
5
mCRC - 2nd line (L2)
6
endometrial cancer
10
chemotherapy
non platinum-based chemotherapy
nucleoside analogues (pyrimidine/purine)
capecitabine
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cometinib
avelumab based treatment
avelumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs placebo plus bevacizumab
vs regorafenib
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
mCRC - 2nd line (L2)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open